Renal cell carcinoma: Where will the state-of-the-art lead us?

Current Oncology Reports

Volumn 12, Issue 3, 2010, Pages 193-201

  Brannon, A Rose ^a   Rathmell, W Kimryn ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Gene expression profile; Renal cell carcinoma; Von hippel lindau

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; TUMOR MARKER; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

CANCER PATIENT; CYTOGENETICS; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; KIDNEY CARCINOMA; MEDICAL TECHNOLOGY; NOMOGRAM; REVIEW; TRANSCRIPTION REGULATION; UPREGULATION; VON HIPPEL LINDAU DISEASE;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NOMOGRAMS;

EID: 77952240400     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0093-4     Document Type: Review

References (56)

1. Cancer Facts and Figures 2009. Atlanta, GA: American Cancer Society, Inc; 2009.
2. F Latif K Tory J Gnarra, et al. 1993 Identification of the von Hippel-Lindau disease tumor suppressor gene Science 260 1317 1320 10.1126/science.8493574 1:CAS:528:DyaK3sXks12htbc%3D 8493574 (Pubitemid 23231974)
3. JR Gnarra K Tory Y Weng, et al. 1994 Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 7 85 90 10.1038/ng0594-85 1:CAS:528:DyaK2cXktlaitbg%3D 7915601 (Pubitemid 24232386)
4. T Shuin K Kondo S Torigoe, et al. 1994 Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas Cancer Res 54 2852 2855 1:CAS:528: DyaK2cXksl2rsLo%3D 8187067
5. PH Maxwell MS Wiesener GW Chang, et al. 1999 The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature 399 271 275 10.1038/20459 1:CAS:528:DyaK1MXjsFyqt74%3D 10353251 (Pubitemid 29246458)
6. MA Maynard H Qi J Chung, et al. 2003 Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex J Biol Chem 278 11032 11040 10.1074/jbc.M208681200 1:CAS:528: DC%2BD3sXit1Kgsro%3D 12538644 (Pubitemid 36792653)
7. K Kondo J Klco E Nakamura, et al. 2002 Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein Cancer Cell 1 237 246 10.1016/S1535-6108(02)00043-0 1:CAS:528:DC%2BD38XjsFGltrY%3D 12086860 (Pubitemid 41039148)
8. O Iliopoulos A Kibel S Gray, et al. 1995 Tumour suppression by the human von Hippel-Lindau gene product Nat Med 1 822 826 10.1038/nm0895-822 1:CAS:528:DyaK2MXnt1ynu7c%3D 7585187
9. CL Cowey WK Rathmell 2009 VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy Curr Oncol Rep 11 94 101 10.1007/s11912-009-0015-5 1:CAS:528:DC%2BD1MXltVSluro%3D 19216840
10. JD Gordan MC Simon 2007 Hypoxia-inducible factors: central regulators of the tumor phenotype Curr Opin Genet Dev 17 71 77 10.1016/j.gde.2006.12.006 1:CAS:528:DC%2BD2sXnslOntw%3D%3D 17208433 (Pubitemid 46109295)
11. M Edgren B Lennernas A Larsson, et al. 1999 Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas Anticancer Res 19 869 873 1:STN:280:DyaK1M3jt1Wmtg%3D%3D 10216508
12. B Berse LF Brown L Van de Water, et al. 1992 Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors Mol Biol Cell 3 211 220 1:CAS:528: DyaK38XitFajsL4%3D 1550962
13. CL Cowey WK Rathmell 2008 Using molecular biology to develop drugs for renal cell carcinoma Expert Opin Drug Discov 3 311 327 10.1517/17460441.3.3.311 1:CAS:528:DC%2BD1cXks1Ciurs%3D (Pubitemid 351425375)
14. CM Lee MM Hickey CA Sanford, et al. 2009 VHL type 2B gene mutation moderates HIF dosage in vitro and in vivo Oncogene 28 1694 1705 10.1038/onc.2009.12 1:CAS:528:DC%2BD1MXisVOrur4%3D 19252526
15. WK Rathmell MM Hickey NA Bezman, et al. 2004 In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations Cancer Res 64 8595 8603 10.1158/0008-5472.CAN-04-1430 1:CAS:528:DC%2BD2cXhtVCjs73O 15574766 (Pubitemid 39552072)
16. •• Gordan JD, Lal P, Dondeti VR, et al.: HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008,14:435-446. In this article, 160 ccRCC tumors were analyzed for VHL genotype and HIF-α expression. Wild-type VHL tumors and HIF1/HIF2-overexpressing tumors have increased AKT/mTOR and ERK/MAPK signaling, while HIF2-only overexpressing tumors have increased c-Myc.
17. •• Dalgliesh GL, Furge K, Greenman C, et al.: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463:360-363. This article details resequencing of 3544 genes in 96 ccRCC tumors, with follow-up sequencing of 60 genes in 246 additional ccRCCs. Genes most mutated involved histone modification and DNA damage repair.
18. KA Furge KA Lucas M Takahashi, et al. 2004 Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles Cancer Res 64 4117 4121 10.1158/0008-5472.CAN-04-0534 1:CAS:528: DC%2BD2cXkvFWls78%3D 15205321 (Pubitemid 38802413)
19. H Sultmann A von Heydebreck W Huber, et al. 2005 Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival Clin Cancer Res 11 646 655 15701852
20. AM Meloni-Ehrig 2002 Renal cancer: cytogenetic and molecular genetic aspects Am J Med Genet 115 164 172 10.1002/ajmg.10697 12407697 (Pubitemid 35265506)
21. • Beroukhim R, Brunet JP, Di Napoli A, et al.: Patterns of gene expression and copy-number alterations in von-Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009, 69:4674-4681. This is an SNP analysis and gene expression analysis of 54 sporadic and 36 VHL disease-associated ccRCC tumors. These two types of ccRCC are very similar, but sporadic tumors are more heterogeneous and contain more genotypic changes.
22. •• Klatte T, Rao PN, de Martino M, et al.: Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009, 27:746-753. This is a prospective study of cytogenetic abnormalities in 282 sporadic ccRCC patients, identifying the retention of 3p and loss of 4p, 9p, and 14q to be associated with poor survival. Loss of 9p was incorporated into a UISS-modified nomogram.
23. L Dunn A Demichele 2009 Genomic predictors of outcome and treatment response in breast cancer Mol Diagn Ther 13 73 90 1:CAS:528:DC%2BD1MXpvFehtrs%3D 19537843
24. M Takahashi DR Rhodes KA Furge, et al. 2001 Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification Proc Natl Acad Sci U S A 98 9754 9759 10.1073/pnas.171209998 1:CAS:528:DC%2BD3MXmtlCms74%3D 11493696 (Pubitemid 32769376)
25. JR Vasselli JH Shih SR Iyengar, et al. 2003 Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor Proc Natl Acad Sci U S A 100 6958 6963 10.1073/pnas.1131754100 1:CAS:528:DC%2BD3sXkslOntL8%3D 12777628 (Pubitemid 36706375)
26. K Shioi A Komiya K Hattori, et al. 2006 Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients Clin Cancer Res 12 7339 7346 10.1158/1078-0432.CCR-06-1737 1:CAS:528: DC%2BD28XhtlCrtr%2FN 17189405 (Pubitemid 46095406)
27. M Yao Y Huang K Shioi, et al. 2008 A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma Int J Cancer 123 1126 1132 10.1002/ijc.23641 1:CAS:528:DC%2BD1cXhtVSrsLjF 18546273
28. J Jones H Otu D Spentzos, et al. 2005 Gene signatures of progression and metastasis in renal cell cancer Clin Cancer Res 11 5730 5739 10.1158/1078-0432.CCR-04-2225 1:CAS:528:DC%2BD2MXos1Cjsbs%3D 16115910 (Pubitemid 41170297)
29. F Kosari AS Parker DM Kube, et al. 2005 Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness Clin Cancer Res 11 5128 5139 10.1158/1078-0432.CCR-05-0073 1:CAS:528: DC%2BD2MXmt12qtb8%3D 16033827 (Pubitemid 41003697)
30. AS Parker F Kosari CM Lohse, et al. 2006 High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma Cancer 107 37 45 10.1002/cncr.21952 1:CAS:528:DC%2BD28XntVymtbk%3D 16736510 (Pubitemid 43939028)
31. AS Parker BC Leibovich CM Lohse, et al. 2009 Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma Cancer 115 2092 2103 10.1002/cncr.24263 19296514
32. • Zhao H, Ljungberg B, Grankvist K, et al.: Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med 2006, 3:e13. This is a gene expression microarray analysis of 177 tumors, delineating two primary and five subclusters of ccRCC.
33. H Zhao M Zongming R Tibshirani, et al. 2009 Alteration of gene expression signatures of cortical differentiation and wound response in lethal clear cell renal cell carcinomas PLoS One 4 e6039 10.1371/journal.pone.0006039 19557179
34. M Nogueira HL Kim 2008 Molecular markers for predicting prognosis of renal cell carcinoma Urol Oncol 26 113 124 1:CAS:528:DC%2BD1cXivVygsbw%3D 18312928
35. KM Skubitz W Zimmermann R Kammerer, et al. 2006 Differential gene expression identifies subgroups of renal cell carcinoma J Lab Clin Med 147 250 267 10.1016/j.lab.2006.04.001 1:CAS:528:DC%2BD28Xks1Wrurc%3D 16697773 (Pubitemid 43668482)
36. Brannon AR, Reddy A, Seiler M, et al.: Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes and Cancer 2010, 1:152-163.
37. C Dahinden B Ingold P Wild, et al. 2010 Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer Clin Cancer Res 16 88 98 10.1158/1078-0432.CCR-09-0260 1:CAS:528:DC%2BC3cXot1Wl 20028743
38. JL Perez-Gracia C Prior F Guillen-Grima, et al. 2009 Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array Br J Cancer 101 1876 1883 10.1038/sj.bjc.6605409 1:CAS:528:DC%2BD1MXhsVOhtLjK 19904265
39. BI Rini MD Michaelson JE Rosenberg, et al. 2008 Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma J Clin Oncol 26 3743 3748 10.1200/JCO.2007.15. 5416 1:CAS:528:DC%2BD1cXhtVGjs73L 18669461
40. SE Deprimo CL Bello J Smeraglia, et al. 2007 Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins J Transl Med 5 32 10.1186/1479-5876-5-32 17605814 (Pubitemid 47226331)
41. C Nakada K Matsuura Y Tsukamoto, et al. 2008 Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c J Pathol 216 418 427 10.1002/path.2437 1:CAS:528: DC%2BD1MXlvVWrtw%3D%3D 18925646
42. TF Chow YM Youssef E Lianidou, et al. 2009 Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis Clin Biochem 43 150 158 10.1016/j.clinbiochem.2009.07.020 19646430
43. Juan D, Alexe G, Antes T, et al.: Identification of a microRNA panel for clear-cell kidney cancer. Urology 2009 Dec 24 (Epub ahead of print).
44. D Petillo EJ Kort J Anema, et al. 2009 MicroRNA profiling of human kidney cancer subtypes Int J Oncol 35 109 114 10.3892/ijo-00000318 1:CAS:528:DC%2BD1MXosFSlsr8%3D 19513557
45. S Sinha S Dutta K Datta, et al. 2009 Von Hippel-Lindau gene product modulates TIS11B expression in renal cell carcinoma: impact on vascular endothelial growth factor expression in hypoxia J Biol Chem 284 32610 32618 10.1074/jbc.M109.058065 1:CAS:528:DC%2BD1MXhsVSmur3M 19801654
46. V Ficarra A Galfano M Mancini, et al. 2007 TNM staging system for renal-cell carcinoma: current status and future perspectives Lancet Oncol 8 554 558 10.1016/S1470-2045(07)70173-0 17540307 (Pubitemid 46805912)
47. A Zisman AJ Pantuck F Dorey, et al. 2001 Improved prognostication of renal cell carcinoma using an integrated staging system J Clin Oncol 19 1649 1657 1:STN:280:DC%2BD3M3gsl2gtA%3D%3D 11250993 (Pubitemid 32230864)
48. MW Kattan V Reuter RJ Motzer, et al. 2001 A postoperative prognostic nomogram for renal cell carcinoma J Urol 166 63 67 10.1016/S0022-5347(05)66077-6 1:STN:280:DC%2BD3MznslGitg%3D%3D 11435824
49. I Frank ML Blute JC Cheville, et al. 2002 An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score J Urol 168 2395 2400 10.1016/S0022-5347(05)64153-5 12441925
50. M Sorbellini MW Kattan ME Snyder, et al. 2005 A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma J Urol 173 48 51 15592023
51. RJ Motzer M Mazumdar J Bacik, et al. 1999 Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 2530 2540 1:STN:280:DC%2BD3c%2FjtVSnug%3D%3D 10561319 (Pubitemid 29368255)
52. TM Mekhail RM Abou-Jawde G Boumerhi, et al. 2005 Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma J Clin Oncol 23 832 841 10.1200/JCO.2005.05.179 15681528 (Pubitemid 46224183)
53. BC Leibovich JC Cheville CM Lohse, et al. 2005 A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials J Urol 174 1759 1763 10.1097/01.ju.0000177487.64651.3a 16217278 discussion 1763 (Pubitemid 41546928)
54. • Isbarn H, Karakiewicz PI: Predicting cancer-control outcomes in patients with renal cell carcinoma. Curr Opin Urol 2009, 19:247-257. This review clearly summarizes pre-nephrectomy and post-nephrectomy nomograms for recurrence, as well as survival prediction algorithms for nonmetastatic and metastatic disease.
55. HL Kim D Seligson X Liu, et al. 2005 Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma J Urol 173 1496 1501 10.1097/01.ju.0000154351.37249.f0 1:CAS:528:DC%2BD2MXjtFalsrk%3D 15821467 (Pubitemid 40524757)
56. V Ficarra L Schips F Guille, et al. 2005 Multi-institutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma Cancer 104 968 974 10.1002/cncr.21254 16007683 (Pubitemid 41170224)